Published in Int J Mol Med on April 24, 2014
Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci (2000) 10.77
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol (1988) 8.61
Systematic identification and analysis of exonic splicing silencers. Cell (2004) 8.50
Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev (2004) 4.59
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Splicing in action: assessing disease causing sequence changes. J Med Genet (2005) 3.07
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat (2008) 2.31
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet (2000) 2.20
Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res (2004) 1.65
Mechanism for cryptic splice site activation during pre-mRNA splicing. Proc Natl Acad Sci U S A (1990) 1.60
Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet (2003) 1.59
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat (2010) 1.47
RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci U S A (2008) 1.45
Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat (2004) 1.35
Neurofibromin: a general outlook. Clin Genet (2006) 1.31
Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat (2008) 1.30
Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus (2010) 1.27
Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption. Hum Mutat (2007) 1.17
Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet (2003) 1.15
Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem (2003) 1.13
Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer (2007) 1.07
Enhancers and silencers: an integrated and simple model for their function. Epigenetics Chromatin (2012) 1.05
NF1 exon 7 skipping and sequence alterations in exonic splice enhancers (ESEs) in a neurofibromatosis 1 patient. Hum Genet (2003) 1.00
A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet (2013) 0.93
Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1. Pediatr Neurol (2013) 0.91
Complex splicing pattern generates great diversity in human NF1 transcripts. BMC Genomics (2002) 0.91
Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in Slovak patients. Ann Hum Genet (2013) 0.90
Functional properties and evolutionary splicing constraints on a composite exonic regulatory element of splicing in CFTR exon 12. Nucleic Acids Res (2009) 0.84
NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Hum Mutat (2002) 0.78